{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:04:50Z","timestamp":1789365890418,"version":"build-2803163510"},"reference-count":59,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuroprotection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real\u2010world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter, single\u2010arm, prospective, observational real\u2010world study enrolled 18 patients, including 10 with anti\u2010N\u2010methyl\u2010\n                      <jats:sc>d<\/jats:sc>\n                      \u2010aspartate receptor (NMDAR) encephalitis and 8 with anti\u2010leucine\u2010rich glioma\u2010inactivated 1 (LGI1) encephalitis. Participants received intravenous efgartigimod at a dose of 10\u2009mg\/kg weekly for a total of two to four doses, with or without concomitant immunosuppressive therapy. Anti\u2010NMDAR\u2010IgG\/LGI1\u2010IgG antibody titers, modified Rankin scale (mRS), Clinical Assessment Scale in Autoimmune Encephalitis (CASE), Montreal Cognitive Assessment, Mini\u2010Mental State Examination, and Glasgow Coma Scale scores were assessed at baseline and at 1, 2, 3, 8, and 12 weeks after treatment.\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010DPA714 positron emission tomography\/magnetic resonance imaging was used to monitor brain inflammation in a subset of patients. Analyses were performed using SPSS 26.0 and Prism 10.0. Non\u2010parametric tests, including Wilcoxon signed\u2010rank, Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      , and Friedman tests with Bonferroni post hoc correction, were applied. Two\u2010tailed\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 indicated statistical significance; corrected\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 was applied for five longitudinal pairwise comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the final follow\u2010up, median mRS scores in patients with anti\u2010NMDAR encephalitis decreased significantly from 3 (range, 1\u20135) before treatment to 1 (range, 0\u20133) after treatment (\n                      <jats:italic>Z<\/jats:italic>\n                      \u2009=\u2009\u22122.588,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Median CASE scores decreased from 7.5 (range, 1\u201327) to 1.5 (range, 1\u20137) post\u2010treatment (\n                      <jats:italic>Z<\/jats:italic>\n                      \u2009=\u2009\u22122.714,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). In patients with anti\u2010LGI1 encephalitis, CASE scores decreased markedly from 3 (range, 1\u20137) to 1.5 (range, 0\u20132) at the last visit (\n                      <jats:italic>Z<\/jats:italic>\n                      \u2009=\u2009\u22122.154,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046). All 18 patients underwent baseline imaging, and 7 patients underwent follow\u2010up PET\/MRI examinations. A subset of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094; three with anti\u2010NMDAR encephalitis and one with anti\u2010LGI1 encephalitis) showed reduced uptake in specific brain regions accompanied by symptom improvement. Both initial and follow\u2010up imaging results were negative for the remaining three patients. Comparative analysis of efgartigimod monotherapy versus combination therapy with glucocorticoids and immunosuppressants revealed no significant differences in key outcomes, indicating that the therapeutic effect was independent of concomitant medication use. Efgartigimod was well tolerated. One patient (1\/18) developed mild pneumonia, but no other serious adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efgartigimod may represent a novel therapeutic option for anti\u2010NMDAR and anti\u2010LGI1 encephalitis, potentially improving clinical outcomes in affected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration Info<\/jats:title>\n                    <jats:p>\n                      This study was registered at the National Clinical Research Center (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.medicalresearch.org.cn\">https:\/\/www.medicalresearch.org.cn<\/jats:ext-link>\n                      ; No. MR\u201031\u201024\u2010053225).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nep3.70063","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:56:59Z","timestamp":1789365419000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of efgartigimod in patients with anti\u2010NMDAR or anti\u2010LGI1 encephalitis and its\n                    <sup>18<\/sup>\n                    F\u2010DPA714 PET imaging evaluation: A multicenter, single\u2010arm, prospective, observational real\u2010world study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4038-7206","authenticated-orcid":false,"given":"Huanyu","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0759-1121","authenticated-orcid":false,"given":"Siqi","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruinan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Neurology The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology Nanjing Brain Hospital Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology Qilu Hospital of Shandong University Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology Zhongnan Hospital of Wuhan University Wuhan Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology Union Hospital Affiliated to Fujian Medical University Fuzhou Fujian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Institute of Neurology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577598"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70253-2"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103074"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1"},{"issue":"11","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2\u2010microglobulin\u2010containing neonatal intestinal transport receptor","volume":"93","author":"Junghans RP","year":"1996","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M116.064675","article-title":"A two\u2010pronged binding mechanism of IgG to the neonatal fc receptor controls complex stability and IgG serum half\u2010life","volume":"16","author":"Jensen PF","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"issue":"4","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bdcasr.2024.100052","article-title":"Long\u2010term use of efgartigimod alfa in treating a young adult with childhood\u2010onset systemic lupus erythematosus and generalized myasthenia gravis","volume":"2","author":"Nagatani K","year":"2024","journal-title":"Brain Deve Case Rep"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444288","article-title":"Case report: rapid symptom relief in autoimmune encephalitis with efgartigimod: a three\u2010patient case series","volume":"15","author":"Zhang Q","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12556-1"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230397"},{"issue":"23","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq7595","article-title":"Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell\u2010mediated limbic encephalitis","volume":"9","author":"Gallus M","year":"2023","journal-title":"Sci Adv"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12302-7"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70107"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-022-01411-1"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21050"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq213"},{"issue":"1","key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10928-024-09952-5","article-title":"Translational population target binding model for the anti\u2010FcRn fragment antibody efgartigimod","volume":"52","author":"Hoefman S","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41181-021-00133-0","article-title":"Optimised GMP\u2010compliant production of [(18)F]DPA\u2010714 on the Trasis AllinOne module","volume":"6","author":"Cybulska KA","year":"2021","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12690-w"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07305-z"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70282-5"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490804"},{"issue":"2","key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00701-022-05431-3","article-title":"External validation of the GCS\u2010Pupils Score as an outcome predictor after traumatic brain injury in adults: a single\u2010center experience","volume":"165","author":"Maye H","year":"2023","journal-title":"Acta Neurochir"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.068774"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000518939"},{"issue":"6","key":"e_1_2_11_32_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long\u2010term outcome of patients with autoimmune encephalitis: real\u2010world evidence from the GENERATE registry","volume":"8","author":"Thaler FS","year":"2021","journal-title":"Neurology Neuroimmunol Neuroinflamm"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13291"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578062"},{"issue":"1","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-023-02844-4","article-title":"Transfer of patient's peripheral blood mononuclear cells (PBMCs) disrupts blood\u2010brain barrier and induces anti\u2010NMDAR encephalitis: a study of novel humanized PBMC mouse model","volume":"20","author":"Shu Y","year":"2023","journal-title":"J Neuroinflammation"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01364","article-title":"Selective limbic blood\u2010brain barrier breakdown in a feline model of limbic encephalitis with LGI1 antibodies","volume":"8","author":"Tr\u00f6scher AR","year":"2017","journal-title":"Front Immunol"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2017.05.041"},{"issue":"19","key":"e_1_2_11_38_1","first-page":"1505","article-title":"[Safety of plasma exchange therapy in patients with anti\u2010NMDA receptor encephalitis]","volume":"95","author":"Zhang Y","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790962","article-title":"Immunotherapy for refractory autoimmune encephalitis","volume":"12","author":"Yang J","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2013.10.005"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51313"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01222-x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0298"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07460-5"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"e_1_2_11_46_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1550023","article-title":"Resolution of anti\u2010GAD\u2010associated autoimmune encephalitis in patients treated with efgartigimod","volume":"16","author":"Chen M","year":"2025","journal-title":"Front Neurol"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07843-8"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70280"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.444"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww208"},{"issue":"7","key":"e_1_2_11_51_1","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311049121","article-title":"Ultrahigh frequencies of peripherally matured LGI1\u2010 and CASPR2\u2010reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis","volume":"121","author":"Theorell J","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf096"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2016.04.004"},{"issue":"8","key":"e_1_2_11_54_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3949\/ccjm.88a.20122","article-title":"Antibody\u2010mediated autoimmune encephalitis: a practical approach","volume":"88","author":"Abbatemarco JR","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01178-4"},{"key":"e_1_2_11_56_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00442","article-title":"Hello from the other side: how autoantibodies circumvent the blood\u2010brain barrier in autoimmune encephalitis","volume":"8","author":"Platt MP","year":"2017","journal-title":"Front Immunol"},{"key":"e_1_2_11_57_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1406643","article-title":"Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity","volume":"15","author":"Siegel M","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri856"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673339"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261"}],"container-title":["Neuroprotection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nep3.70063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nep3.70063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nep3.70063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:57:02Z","timestamp":1789365422000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nep3.70063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":59,"alternative-id":["10.1002\/nep3.70063"],"URL":"https:\/\/doi.org\/10.1002\/nep3.70063","archive":["Portico"],"relation":{},"ISSN":["2770-7296","2770-730X"],"issn-type":[{"value":"2770-7296","type":"print"},{"value":"2770-730X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"2026-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"nep3.70063"}}